Corium International, a commercial-stage pharmaceutical company focused on transdermal drug delivery, raised $52 million by offering 6.5 million shares (all primary) at $8, below the range of $10 to $12. The company had originally planned to offer 5.5 million shares (all primary). Existing shareholders planned to buy $8.5 million of the deal. Corium International plans to list on the NASDAQ under the symbol CORI. Corium International initially filed confidentially on 12/23/2013. Jefferies & Co. and Leerink Partners acted as lead managers on the deal.
